Greffex Inc

Showcase Sponsor

Through our innovative and proven technologies, Greffex has invented the future of vaccines and genetic medicine. Our proprietary GREVAX Universal Platform delivers vaccines in a faster and more efficient manner. Once a pathogen has been identified, Greffex’s team can design and produce a GREVAX vaccine within 4 weeks. We have developed systems to manufacture enough vaccines within weeks to immunize the entire US population.

The flexibility of the GREVAX Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, MERS-CoV, Anthrax, Zika and Dengue Fever, as well as Malaria, Hepatitis C, RSV Ebola, HPV, Tuberculosis and other infections.

Our GREVAX Universal Platform in conjunction with Greffex’s proprietary engineered veto strategy allows the development of a new generation of immune evading gene therapy vectors and novel approaches to immune suppression in organ transplantation.